Anna V. Tinker
Impact in
- Reproductive Medicine top 0.05%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Ovarian cancer diagnosis and treatment 45
- Oncology 54
- PARP inhibition in cancer therapy 36
- Cancer Immunotherapy and Biomarkers 17
- Co-authors
- Michael Leonard Friedlander (3 shared papers)C. Blake Gilks (15 shared papers)David D.L. Bowtell (3 shared papers)Joshy George (2 shared papers)Nadia Traficante (2 shared papers)Anna DeFazio (2 shared papers)Richard W. Tothill (2 shared papers)Bianca Locandro (2 shared papers)
- Journals
- Gynecologic Oncology (26 papers)International Journal of Gynecological Cancer (14 papers)Annals of Oncology (13 papers)Clinical Cancer Research (7 papers)The Lancet Oncology (4 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Anna V. Tinker
141 papers receiving 11.6k citations
Anna V. Tinker's Hit Papers
Peers
Comparison fields: 5 of 106
- Reproductive Medicine 4.2k
- Oncology 4.2k
- Obstetrics and Gynecology 924
- Cancer Research 777
- Genetics 1.3k
Countries citing papers authored by Anna V. Tinker
This map shows the geographic impact of Anna V. Tinker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna V. Tinker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna V. Tinker more than expected).
Fields of papers citing papers by Anna V. Tinker
This network shows the impact of papers produced by Anna V. Tinker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna V. Tinker. The network helps show where Anna V. Tinker may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna V. Tinker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 146 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Hit paper breakdown → | 2016 | 2026 |
| 2 | Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome Hit paper breakdown → | 2008 | 1187 |
| 3 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Hit paper breakdown → | 2016 | 991 |
| 4 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer Hit paper breakdown → | 2017 | 368 |
| 5 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study Hit paper breakdown → | 2013 | 357 |
| 6 | “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit? Hit paper breakdown → | 2014 | 357 |
| 7 | 2018 | 356 | |
| 8 | 2017 | 347 | |
| 9 | Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study Hit paper breakdown → | 2021 | 316 |
| 10 | 2020 | 284 | |
| 11 | 2009 | 254 | |
| 12 | 2008 | 247 | |
| 13 | Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study Hit paper breakdown → | 2022 | 241 |
| 14 | 2017 | 238 | |
| 15 | 2015 | 233 | |
| 16 | 2011 | 186 | |
| 17 | 2021 | 170 | |
| 18 | 2012 | 169 | |
| 19 | 2013 | 128 | |
| 20 | 2017 | 127 |
About Anna V. Tinker
Anna V. Tinker is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Genetics and Cancer Research, having authored 146 papers that have together received 11.8k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (45 papers), PARP inhibition in cancer therapy (36 papers), Endometrial and Cervical Cancer Treatments (27 papers), Cancer Immunotherapy and Biomarkers (17 papers), BRCA gene mutations in cancer (11 papers), Cancer Genomics and Diagnostics (6 papers), Cervical Cancer and HPV Research (3 papers) and Gestational Trophoblastic Disease Studies (2 papers). The work is most often cited by research in Reproductive Medicine (4.2k citations), Oncology (4.2k citations), Obstetrics and Gynecology (924 citations), Cancer Research (777 citations) and Genetics (1.3k citations). Anna V. Tinker has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Michael Leonard Friedlander, C. Blake Gilks, David D.L. Bowtell, Joshy George, Nadia Traficante, Anna DeFazio, Richard W. Tothill, Bianca Locandro, Sián Fereday and Georgia Chenevix‐Trench. Their work appears in journals such as Gynecologic Oncology, International Journal of Gynecological Cancer, Annals of Oncology, Clinical Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.